SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (”SaaS”) platform, posted a video on YouTube featuring founder and CEO Christopher Miglino along with CFO Michael Malone outlining the company’s operational and financial summary for Q1 2021. Highlights of the company’s financial report included the announcements that year-over-year revenue growth for the company was up 1,400%, with growth for Sequire alone up 2,800%; the company also increased its guidance for the year. Technology highlights from the report included the launch of the Sequire audience platform, where companies can host earnings calls, annual meetings and roadshows; the company launched the platform in partnership with Zoom. To view the full video, visit https://ibn.fm/UPsX5

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

• SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
• SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
• SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
• SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
• SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
• SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday’s trading session at $4.55, up 5.0808%, on 493,762 volume. The average volume for the last 3 months is 803,834 and the stock's 52-week low/high is $1.60000002/$7.19500017.

Recent News

• InvestorNewsBreaks - SRAX (NASDAQ: SRAX) Releases Q1 Revenue Growth, Increases Full-Year Guidance
• InvestorNewsBreaks - SRAX (NASDAQ: SRAX) Sees Q1 Revenue Growth, Increases Full-Year Guidance
• SRAX Inc.'s (NASDAQ: SRAX) Sequire Marks 5M Retail Investors, Hosts LD Micro Invitational

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2).

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) was featured today in a publication from MiningNewsWire, examining how a report released recently by Adamas Intelligence predicts that the overall market for magnetic rare earth oxide minerals will shoot up from its current size of $2.98 billion to $15.65 billion by 2030. The report indicates that the major driver for this massive growth is the total demand for these magnet rare earths, a demand which is anticipated to grow at a 9.7% CAGR, as well as the price of the metals, which is expected to grow at a 5.6 to 9.9% CAGR over the review period. The report also adds that raw material shortages will play a key part in this market.

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://nnw.fm/6nv5f). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 (https://nnw.fm/6nv5f). Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (https://nnw.fm/6nv5f).

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

• Silver – 355,581 oz – $24.46
• Lead – 2,223,465 lbs. – $0.87
• Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://nnw.fm/4C0P7).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://nnw.fm/jMah9). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Wednesday’s trading session at $2.98, up 0.675676%, on 73,342 volume. The average volume for the last 3 months is 48,504 and the stock's 52-week low/high is $2.19499993/$3.90000009.

Recent News

• Rare Earth Oxides Market to Register a Fivefold Increase by 2030
• MiningNewsBreaks - Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Finds Compelling Results at Platosa Mine
• InvestorNewsBreaks - Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Releases Q1 2021 Financial, General Meeting Report

Gage Cannabis Co. (CSE: GAGE)

The QualityStocks Daily Newsletter would like to spotlight Gage Cannabis Co. (CSE: GAGE).

Gage Growth Corp. (CSE: GAGE) (d.b.a. Gage Cannabis) was featured today in the 420 with CNW by CannabisNewsWire. Last week, Rep. Eleanor Holmes Norton reintroduced a legislation that would allow individuals who live in public housing to use cannabis without living in terror of being evicted. Currently, individuals who live in federally subsidized housing are banned from using any controlled substances, even if those substances are in compliance with state law. Additionally, landlords are allowed to evict individuals who do so, regardless of state law. This bill introduced by the congresswoman would change this.

Gage Growth Corp. was featured today in the 420 with CNW by CannabisNewsWire. A DR Z Leaf dispensary in the state of Oklahoma recently filed a suit in an attempt to stop the execution of a cannabis tracking program in the coming weeks. The litigation, which was filed by the medical cannabis operator, also disputes whether the state’s Department of Health is operating ultra vires by implementing the seed to sale system and making it mandatory for more than 10,000 medical marijuana businesses to pay for it.

Gage Cannabis Co. (CSE: GAGE) is a leading vertically integrated operator in the cannabis industry led by the former CEO and Chairman of Canopy Growth Corp. (TSX: WEED) (NYSE: CGC), Bruce Linton. The company is currently focused exclusively on the Michigan market, working with the declared goal of building the fastest growing cannabis brand in the state.

One of the reasons Gage targeted Michigan as its location of choice is due to the state’s fast-growing legal cannabis market and consumption habits amongst consumers. In 2018, Michigan became the 10th state to legalize the recreational use of cannabis. In light of such favorable market dynamics, Gage opened its first medical provisioning center (dispensary) shortly after, in 2019. The company now has 13 medical or adult-use locations open or in the works, with an additional 10+ planned to open during 2021. Gage’s current portfolio features 19 Class C cultivation licenses across four cultivation assets and three processing licenses.

Current Asset and Brand Portfolio

Gage’s current brand portfolio consists of five unique product classes: flower products, edibles, hardware, concentrates and vape pens/disposables.

The company has already created relationships with a wealth of exclusive brand partners, including some of the most illustrious brands in the country. Notably, Gage’s exclusive partnership with Cookies, one of the most well-respected cannabis lifestyle brands in the United States, illustrates Gage’s operational prowess in cultivating quality flower and operating its branded retail stores. Today, Gage operates the 8 Mile Cookies location in Detroit, Michigan, which is one of the top performing dispensaries in the state despite being a medical-only dispensary.

Committed to providing only products of the highest quality, Gage uses small-batch, indoor-grown, high-quality cannabis that is hand-trimmed and hung to dry. Gage ensures that every gram of cannabis sold is consistently of the highest quality and offers a superb customer experience.

The company currently has four cultivation assets, located at Monitor Township (expansion planned), Harrison Township, Warren and Lenox Township, and it operates one processing facility located in Harrison Township, with plans to operate another two processing facilities in Monitor Township and Lenox.

Its operating dispensaries include Ferndale (adult-use), Adrian (adult-use), Lansing (adult-use), Traverse City (medical) and Detroit (Cookies establishment – medical). Additional dispensaries coming soon include Battle Creek (adult-use), Kalamazoo #1 (adult-use), Bay City (adult-use), Grand Rapids (medical), Buena Vista (medical), Center Line (medical), Kalamazoo #2 (Cookies establishment – adult-use) and Lenox Township.

The company offers delivery within a one-hour radius of its dispensaries – a footprint that encompasses an estimated 90% of Michigan’s population.

Financial Highlights

In Q1 2020, the company recorded sales of $5.8 million. This number grew substantially in Q2, reaching $11.9 million. Management estimates Q3 sales at roughly $13.1 million, marking a 157% growth in sales from January to September 2020, within a year of operations.

This increase reflects the company’s significant expansion efforts since the beginning of 2020. Starting with only 200 pounds per month, Gage now estimates its monthly cultivation capacity at more than 1,000 pounds of product.

This increase in cultivation capacity has helped Gage promote rapid growth through its retail locations. Average basket size, which refers to the retail value of each consumer transaction, is estimated at $85 for the Michigan cannabis industry. As of August 2020, Gage has an average basket size of $180 at its locations, more than double the state average.

Michigan Medical and Adult-Use Marijuana Market Size

The recreational marijuana market in Michigan is expected to rival the numbers currently seen in Nevada and Colorado by 2023. Approximately 3% of Michigan’s residents are medical marijuana cardholders – a much higher rate than many other medical markets – leading Brightfield to predict that the state’s recreational market could triple in size between 2020 and 2023 (https://ibn.fm/9cO0h).

Michigan saw a steady increase in sales for the first three quarters of 2020, with a recorded growth rate of 502% from January to August. In August alone, $109 million in cannabis sales occurred within the state. The Marijuana Regulatory Agency estimates that the potential market size for cannabis within the state is around $3 billion.

Neither Gage nor the state has seen any significant drop in sales in the wake of the COVID-19 pandemic. On the contrary, demand has continued to grow steadily, as dispensaries were among the few businesses deemed essential and permitted to operate throughout the shutdown. All Gage and Cookies locations have remained operational, offering curbside pickup.

Management Team

Bruce Linton is the Executive Chairman of Gage Cannabis. He joined the company in 2019 and is the founder and former CEO and Chairman of Canopy Growth Corp. (TSX: WEED) (NYSE: CGC). Mr. Linton has extensive executive and board experience in a variety of industries and is considered to be a pioneer in the global cannabis industry. He provides incomparable support to the company’s strategic and capital markets efforts.

Michael Hermiz is the Co-Founder and Director of Gage Cannabis, and he is also the founder of a federally licensed producer in Canada. Mr. Hermiz has had great success in various industries, including real estate, mortgage, telecommunications, import, export and many others.

Fabian Monaco is Gage’s President and Director. He previously worked at XIB Financial Inc., GMP Securities L.P. and Scotiabank. In addition to his vast investment banking and legal background, Mr. Monaco has 10+ years of capital markets experience. His advisory experience in the cannabis industry is also extensive.

Dr. Rana Harb is a Director of Gage Cannabis. She has 25+ years of experience handling research, compliance, quality assurance and regulatory affairs. A significant portion of her regulatory and compliance history is in the cannabis industry. Dr. Harb has worked for many pharmaceutical companies worldwide, dealing with regulatory agencies such as the FDA, the EMA and Health Canada.

Mike Finos is the President (USA) and a Director of Gage Cannabis. He is the former COO of Horizon Global, the world’s number one towing accessories company. He has experience with start-ups, M&A and business integration with both private and publicly traded companies. With 20+ years of operational leadership expertise, Mr. Finos has extensive knowledge relating to supply chain logistics, manufacturing and information technology.

David Watza is the Chief Financial Officer of Gage Cannabis. He is an experienced C-Suite executive and former CFO and board member of Perceptron Inc. (NASDAQ: PRCP). Mr. Watza has 30+ years of experience in finance, accounting, and operations, including time as a public company CFO.

Gage Cannabis Co. (CSE: GAGE), closed Wednesday’s trading session at $2.40, up 11.11%. The average volume for the last 3 months is 450,702.

Recent News

• 420 with CNW - Congressional Bill Seeks to Protect Cannabis Consumers from Losing Federally-Assisted Housing
• 420 with CNW - Minnesota House Likely to Vote on Marijuana Legalization Bill This Week
• CSE Reports April 2021 Market Statistics

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today reported the best financial results in nearly three years for the first quarter ended March 31, 2021, provided a business update, and offered guidance for the remainder of FY 2021.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Wednesday’s trading session at $2.05, up 17.8161%, on 11,088 volume. The average volume for the last 3 months is 12,506 and the stock's 52-week low/high is $1.28999996/$3.50.

Recent News

• Pressure BioSciences, Inc. Reports Resurgent Growth with Strong First Quarter 2021 Financial Results and Provides Business Update
• With Sales Up Over 120%, Pressure BioSciences to Host Q1 2021 Financial Results and Business Update on Wednesday, May 19, 2021
• Pressure BioSciences Awarded Three Additional Patents for Revolutionary Ultra Shear Technology Platform

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Wall Street Unicorns in Process of Changing the Healthcare Landscape,” please visit: https://nnw.fm/QOAcO

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

• Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
• Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
• Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Wednesday’s trading session at $0.5638, up 4.4848%, on 91,474 volume. The average volume for the last 3 months is 71,177 and the stock's 52-week low/high is $0.449999988/$1.03999996.

Recent News

• Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Diversified Pipeline to Psychedelic Revival
• Wall Street Unicorns in Process of Changing the Healthcare Landscape
• InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in "Forbes" Article

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Per the update, the company is on target to demonstrate the i/Blue Imaging System(TM) in private meetings during the American Urology Association (“AUA”) meeting to be held in early September. The product will showcase updates to meet performance criteria against competitive products and enhancements made to the design for manufacturing. To view the full press release, visit https://ibn.fm/0uH5M

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Wednesday’s trading session at $0.4257, up 1.3571%, on 11,175 volume. The average volume for the last 3 months is 13,208 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

• InvestorNewsBreaks - Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces On-Track Progress for Demonstration of i/Blue Imaging System(TM)
• BioMedNewsBreaks - Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Eyes 'Exceptional' Work to Move i/Blue Imaging System(TM) into Commercial Manufacturing
• Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology, will Potentially Reduce High Bladder Cancer Recurrence Rates

Grapefruit USA Inc. (OTCQB: GPFT)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit USA Inc. (OTCQB: GPFT).

Grapefruit USA Inc. (OTCQB: GPFT) was featured today in the 420 with CNW by CannabisNewsWire. The Drug Enforcement Administration (“DEA”) has informed some companies that their applications to become federally authorized manufacturers of cannabis for research purposes may soon be approved. This comes nearly five years after the DEA announced that it was accepting applications for new manufacturers, under former President Barack Obama’s administration. This is a significant development, especially when one considers that no approvals were made under the Trump administration, and this is one of the first marijuana-related moves made by the Biden administration.

Grapefruit USA Inc. (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products.

The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses.

Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace.

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids.

Hourglass™ allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

Hourglass™ provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) in a Patchless Patch™ system that is novel and proprietary to the company.

Hourglass™ Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass™ by Grapefruit.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.

Grapefruit Cannabis Services

Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

• Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass™ topical delivery cream.
• Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass™ cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
• Hourglass™ Topical THC+CBD Delivery Cream – The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
• Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook

The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://nnw.fm/eTMSX).

Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology.

Management Team

Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility.

Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations.

Grapefruit USA Inc. (OTCQB: GPFT), closed Wednesday’s trading session at $0.1149, up 8.0903%, on 515,095 volume. The average volume for the last 3 months is 968,401 and the stock's 52-week low/high is $0.013624999/$0.310000002.

Recent News

• 420 with CNW - DEA Announces It May Soon Federally Authorize New Cannabis Manufacturers
• CBDNewsBreaks - Grapefruit USA Inc. (GPFT) Able to Tailor Hourglass (TM) to Specific Needs
• Grapefruit USA Inc. (GPFT) Releases FY2020 Financial Report, Notes 714% Revenue Growth

Sonoma Biologics Corp.

The QualityStocks Daily Newsletter would like to spotlight Sonoma Biologics Corp.

Sonoma Biologics, a producer of high-quality, low-cost cannabis, was founded by the Caracciolos, who had a background in science, specifically in the biotech industry. This background has influenced the founders’ operations, helping them develop standard protocols for cultivation, precisely calibrated to grow high-quality crops. This approach was key in building Sonoma’s reputation as a grower of ultra-premium Pinot Noir grapes, making it a supplier of these grapes to world-class winemakers in the Russian River Valley of Sonoma County. With the legalization of cannabis in California, Sonoma then ventured into hemp cultivation and has utilized a similar science-based approach. A recent article reads, “Just as other winemakers came to them for their grapes, cannabis start-ups reached out to them for varietal knowledge in Sonoma county, as the Caracciolos had already tested and piloted tens of varietals in their first year for climate suitability… By using exclusively organic methods to grow and taking advantage of the suitable Sonoma county climate, the company produces premium quality crops at a fraction of the cost of its competitors.” To view the full article, visit https://ibn.fm/d2thH

Sonoma Biologics Corp. is an ultra-premium cannabis grower focused on the medicinal and recreational cannabis markets. The company’s business model includes acquiring additional farming/cultivation properties in the prestigious wine counties of California, as well as continuing to enter into joint ventures and revenue sharing cultivation opportunities with other landowners/farmers/vineyards. The company’s goal is to become one of the largest organic-equivalent, environmentally friendly cannabis suppliers in northern California.

Sonoma Biologics’ use of solar power in its low cost, highly efficient growth processes exemplifies the company’s commitment to having as close to zero environmental impact as possible.

The company currently holds local and state cannabis cultivation licenses for its existing facilities. Since entering the cannabis industry, Sonoma Biologics products have passed stringent California quality control laboratory testing each year. The company exclusively adheres to organic cultivation methods, reinforcing its commitment to yielding the highest quality cannabis.

Sonoma Biologics is currently prepping to certify with the State of California’s comparable-to-organic cannabis standards. The OCal Program will ensure that cannabis products bearing the OCal seal have been certified to consistent, uniform standards comparable to the National Organic Program.

Current Operations

Sonoma Biologics has been cultivating premium cannabis outdoors for the last four years, taking advantage of the favorable climate in its operating region. The company is currently aggressively expanding its model. As the California weather minimizes the need for climate control technology and artificial lighting, the company boasts a significantly lower cost of production when compared to both indoor and outdoor grow operations in areas with less suitable climates. The company pours its efforts into screening and optimizing specific genetic strains that grow the best in local farming conditions, thereby maximizing its yields and taking full advantage of the well-known benefits of the Sonoma soils.

Locations

Sonoma Biologics’ target locations span three well-known wine country counties in California: Sonoma County, Mendocino County and Lake County.

The company’s current locations in Sonoma County provide for up to two acres of outdoor cultivation (pending licensing and county regulations).

The company has a Mendocino joint venture (JV) agreement, which, when completed, will expand its overall cannabis related assets and operations. The joint venture provides the company with additional licensed cultivation, licensed nursery operation, potential dispensary (pending licensing) and employees.

Manufacturing

Highlights of the company’s manufacturing capabilities with the JV include:

• An existing 5,000 square foot warehouse currently being built out to facilitate manufacturing and distribution and
• Additional proposed facilities to manufacture cannabis-related products.

With applications for manufacturing currently in process, these facilities offer further scalability opportunities for the company. Additionally, the Anderson Valley location can intake surplus cannabis from numerous licensed farms in the region and focus on “onsite” and “managed” streams for superior economics.

Investing in California Cannabis

Sonoma Biologics is currently accepting investments from accredited investors under Rule 506(c) of Regulation D. The minimum investment amount is $5,000 per investor, with the overall goal of raising $10 million. The company is also preparing a Reg A+ filing with the SEC for summer 2021. In alignment with its environmentally low impact business strategy, the company has created a streamlined, completely paperless online subscription process for investors.

The company offers those looking to invest in California-grown cannabis the opportunity to invest at an attractive valuation. Sonoma Biologics’ operations are large-scale, low-cost and managed by industry leaders with experience in large-scale farming, making the company an attractive investment opportunity in the expanding cannabis market in California and worldwide.

The global legal cannabis market is estimated to reach $84 billion by 2028, expanding at a CAGR of 14.3% from 2021 to 2028 (https://nnw.fm/M5sZo). Of the $24.6 billion in global cannabis industry revenue reported in 2020, 60.3% was attributed to the recreational adult-use segment. Furthermore, 91.1% of the revenue can be attributed to North America, spurred by early legalization of medical and recreational cannabis in a number of jurisdictions (https://nnw.fm/r4gUg).

The California market for cannabis is expected to reach $6 billion by 2025 and account for roughly a sixth of all legal cannabis sales in the United States (https://nnw.fm/bNDJE).

Management Team

Paul Caracciolo is the Chief Executive Officer and Co-Founder of Sonoma Biologics Corp. He has a Master’s in Biochemistry from the University of Colorado. After obtaining his degree, he developed human-grade biopharmaceuticals for a company that was eventually acquired by Amgen. Mr. Caracciolo has spent much of his career in the health care industry, holding positions such as Chief Technology Officer for Dignity Health, Duke University Health System and Stanford’s Hospitals and Clinics. In 2008, Mr. Caracciolo and his wife, Margaret, founded Mill Station Vineyards. Mill Station spans 8.5 acres of ultra-premium Pinot Noir grapes, sold and used in some of the most coveted Pinot Noir blends in the Russian River Valley.

Hal Reuling is the owner of the Anderson Valley Property. He has a long history of real estate development and management projects, from inception to realization. He began his career as a general contractor in Colorado, establishing Bluefootprint Construction and specializing in single-family and custom-built homes. Mr. Reuling’s next venture took him to Florida, where he developed raw land parcels into subdivisions. In 2007, he moved to Northern California to capitalize on property development, including that of the cannabis industry. Durango Organics approached Mr. Reuling in 2015 to design and build a 20,000 square foot fully integrated cultivation facility. More recently, he developed a 110-acre, 11-lot cultivation site in Southern Colorado. He purchased the Anderson Valley Property in 2016 as California began passing cannabis laws. Now, it is being used for co-developing into cultivation, nursery and manufacturing.

Directors

Alexander Somjen, Director, has extensive experience serving as an officer and director of publicly listed and privately held companies. Since December 2019, he has served as President of Hollister Cannabis Inc., a diversified, multi-state cannabis company whose securities are quoted on the Canadian Securities Exchange (CSE) and the OTC Pink Market maintained by OTC Markets. Hollister provides manufacturing and white label services to help build new brands and support influencers and is also involved with the manufacturing of various cannabis related products (such as pre rolls, capsules and vape formulation). Additionally, since January 2018, he served as President and CEO of Global Care Capital Inc. (formerly Rescinco Capital Partners Inc.), whose securities are quoted on the CSE and the OTC Pink Market. Global Care Capital is a global investment company which specializes in providing early-stage financing to private and public companies. Global Care Capital also has a sector focus on cannabis pharmaceutical opportunities. Mr. Somjen was Vice President of Capital Structure Products at Desjardins Capital Markets from January 2015 to January 2018, where he served as the co-head of the Capital Structure Products desk and advised issuers (namely banks) on subordinated debt and hybrid and preferred share markets. He held other roles with Desjardins Capital Markets from January 2008 to January 2015, including serving as an associate in the fixed income group (January 2012 to January 2015) and as a trader in the fixed income group (January 2008 to January 2012). Mr. Somjen received a bachelor’s degree in economics from the University of Toronto and is working to obtain an Executive MBA from the Instituto de Empresa Business School (IE) in Madrid, Spain.

Robert James Metcalfe, a Lawyer, was a senior partner with the law firm Lang Michener LLP for 20 years. He is the former President and Chief Executive Officer of Armadale Properties and Counsel to all of the Armadale Group of Companies, with significant holdings across numerous industries including finance, construction of office buildings, airport ownership, management and refurbishing, land development, automotive dealerships as well as newspaper publishing, radio and television stations. Mr. Metcalfe was a director of Canada Lands Company Ltd., one of the largest real estate corporations in Canada, and was a director and Chairman of the Board of the CN Tower Ltd., the tallest communications structure in the world. Mr. Metcalfe has served as a director of numerous public and private corporations and currently serves as a director of publicly listed companies Gran Colombia Gold (Lead Director), Blue Star Gold (Chairman), Medcolcanna Organics (Chairman), Pasofino Gold and BetterLife Pharma Ltd. (Chairman). As director and shareholder, Mr. Metcalfe has been engaged in numerous acquisitions, divestitures, corporate reorganizations, financings and corporate improvements, as well as serving on numerous special committees across many sectors. He is a member of the Institute of Corporate Directors and a member in good standing of the Law Society of Upper Canada.

Recent News

• InvestorNewsBreaks – Sonoma Biologics Corp. Stands Distinct with Science-Based Approach
• Sonoma Biologics Corp., Where Science Meets Lifestyle in a Unique Organic Product Line
• InvestorNewsBreaks – Sonoma Biologics Corp. Capable of Large-Scale Production in Heart of California’s Wine Country

Emaginos Inc.

The QualityStocks Daily Newsletter would like to spotlight Emaginos Inc..

Emaginos is on a mission to use proven best practices to solve the existential problems plaguing the K-12 public education system in the U.S., which numerous studies have described as broken and one that cannot be fixed. However, Emaginos holds a different view. Through its game-changing model that implements the Emaginos Discovery Learning System (“DLS”), the company is transforming “the current teacher-centered model to a K-12 public education system that fosters and supports a student’s desire to learn.” A recent article further reads, “The game-changing Emaginos model uses existing facilities, teachers and administrators and can be implemented within existing budgets using proven best practices. ‘It is time to stop wasting money patching and repairing a system that is obsolete,’ states the Emaginos website. ‘It is time to transform the system, integrating the best practices available while discarding the sacred cows that have held back true reform.’” To view the full article, visit https://ibn.fm/tzaFH

Emaginos Inc. is working to improve the education system of the United States through a commitment to integrated, proven best practices. Opposed to replacing public schools with charter schools, Emaginos believes in restoring neighborhood schools and having them serve as focal points of their communities.

Through the company’s model, one school in a district is transformed into a charter. This allows the district to write a separate contract for the teachers in the pilot school. The pilot school incorporates the new model into the community and proves the concept. The lessons learned from this charter are then used to transition the model to the other public schools, adapting them to the model while remaining public.

To achieve this transformation, Emaginos provides the schools with a wealth of resources ranging from technology infrastructure to curriculum training. The schools transformed by the model operate with economic efficiencies squarely in mind, resulting in a better educational experience for the same or lower overall cost.

The company is a REG-A+ Tier 2 public company raising capital for future development and deployment of its transformational public-school model, with the goal of changing the way public schools approach learning.

Emaginos was founded in 2008.

Program Elements

The Emaginos program provides various elements aimed at making the model successful, including:

• Learning Environment: Integrated and proven best practices, multi-level classrooms, diverse small group settings, magnet programs, etc.
• Curriculum: Education customized for individuals, no textbooks, observational assessment rubrics, no more teaching to the test, STEM integration, etc.
• School Calendar: Longer school day, longer school year, internships, college courses, etc.
• Staffing: Teacher mentoring, highly qualified teachers, teacher pay, union support, etc.
• Technology: Technology integration, videoconferencing and telepresence, administrative software, student technical support, etc.
• Wellness and Primary Health Care: Telemedicine, primary health care, wellness simulations, etc.
• Scalable and Transformational: Operates within existing budgets, accountability, research center, national leadership, etc.
• Additional Benefits: Grassroots, unanimity planning, dropout prevention, attendance, etc.

Emaginos Investment Model

Emaginos is focused on changing the way that public school transformation is approached. While many in the industry are in favor of the transition to charters or homeschooling, the company believes in keeping the same buildings and teachers while implementing new proven best practices within the existing budget.

Some key figures relating to the public school system include:

• There are 98,328 public K-12 schools.
• Total public-school enrollment exceeds 50 million.
• The public school system employs more than 3.1 million teachers.
• Total funding of public education amounts to roughly $597.5 billion, with federal funding accounting for 12.7%, state funding accounting for 43.5% and local funding accounting for 43.8% of the total.

The Emaginos model is not a one-time product sale; it is a subscription service that provides the necessary resources for the public school to transition from traditional “teaching and testing” models to the “learning and doing” model.

The Cost of the Emaginos Model

Emaginos’ start-up costs are significant as it builds the EdManage platform and its student centered, multidisciplinary, textbook-free, learning-team, project-based curriculum. However, after the platform and curriculum are built, the company expects to incur relatively small incremental costs to sell, deliver and support the program.

Even though districts are required to pay for the model and annual subscription, overall, they are expected to come out even or on top in terms of expenditure. With no more textbooks and no need for additional technology, schools can go without extra support staffing, allowing for additional cost savings.

Management Team

Dr. Keith Larick is the man who developed the Emaginos plan. As a superintendent within the Tracy Unified School District (TUSD) 20 years ago, Dr. Larick chose three educators with whom to work, with the goal of changing education. He challenged these educators to take a clean slate approach to design the optimal K-12 education program. Using proven student-centered and organizational best practices, the result was the creation of three charter schools proving the new K-12 model.

Allan Jones is the President of Emaginos Inc. He has spent over 40 years working in and around education. He was a classroom teacher, district chief information and technology officer in the public school system, and taught college courses for teachers. Mr. Jones also served as a school board member. He co-founded an online high school, consulting with school districts on technology planning, and worked for Digital Equipment Corporation’s corporate research division. While there, he created programs to identify and transfer ideas from leading universities into the company. After all those years of seeing the good, bad, and ugly within the American public school system, he joined Dr. Larick to transform America’s schools into centers of discovery and innovation.

The late Jack Taub was the Chief Visionary of Emaginos Inc. He was from Brooklyn, New York, and dropped out of school to pursue a passion for stamp collecting. He and his brother Bert, both respected philatelists, developed a successful stamp selling business. At one time, they even had an exclusive contract with the USPS, selling their stamp-collecting materials across the country. From those earnings, the brothers invested in what would be considered one of the first social networking applications – though the term didn’t exist yet. Neither brother had a good experience within the K-12 school system, so they turned their sights on fixing it. They teamed up with Dr. Larick to design new models for education adhering to the idea that all students can succeed in education.

Recent News

• InvestorNewsBreaks – Emaginos Inc. Integrating Proven Best Practices to Transform Public Education
• InvestorNewsBreaks – Emaginos Inc.’s Proven System Encourages a Student’s Desire to Learn
• Emaginos Inc. Education Model Leverages Power of Longer School Days, Years

BAND Royalty

The QualityStocks Daily Newsletter would like to spotlight BAND Royalty.

Music entertainment technology company BAND Royalty made a bit of history when it closed its first private presale of a select group of non-fungible tokens (“NFTs”) that not only provide their holders with collectible digital art but also give those  holders an opportunity to share in the song royalties that BAND Royalty owns that are tied to prominent artists’ performances. The BAND NFTs provide digital (blockchain), non-copyright ownership of art-and- the performance royalty selections that feature well-known and popular artists such as Beyoncé, Justin Timberlake, Rihanna, will.i.am, and Jay-Z, and an opportunity to share in the performance royalties generated by the catalog owned by BAND Royalty.

BAND Royalty (operated by Singapore-based LIBERTY IS PTE LTD) is the leading innovator of music-focused NFTs. BAND is an entertainment technology-driven firm focused on the distribution of non-fungible tokens (NFTs) that allow fans to earn royalties from top songs and artists worldwide.

BAND Royalty lets fans take their enjoyment of music to the next level by offering blockchain-secured BAND NFTs that enable holders to earn crypto from some of the world’s most popular songs. This unique opportunity allows individuals to share in income streams each time a song in the BAND Royalty music catalog is performed.

BAND’s royalty pools leverage a performance music catalog featuring tracks from some of the biggest names in music, including Beyonce, Jay-Z, Justin Timberlake, Cher, will.i.am, Timbaland, Missy Elliott and Rihanna.

BAND Royalty NFTs

BAND NFTs, hosted on the ethereum blockchain, are a special type of NFT that can be staked into any one of three BAND Royalty Music Pools to receive a portion of all royalty streaming income from each track, for each royalty pool category. The BAND ecosystem is supported by multiple types of transactions:

• Trading BAND Royalty NFTs – The first ever issuance of BAND NFTs is being offered to the public. Owners of the BAND NFTs will be able to trade them on the largest NFT marketplace, OpenSea, where the BAND NFTs are being launched on May 5, 2021.
• Music Royalty Pools – These blockchain BAND NFTs have a special DeFi (decentralized finance) utility. Holders of BAND NFTs have the option to stake their tokens for a period of 90 days to five years, with longer stakes receiving proportionally increased amounts of the royalties share. Holders have the option to trade their BAND NFTs or stake them in one of three special music catalog pools that provide access to BAND music royalties. The three types of music pools available for staking are print music, mechanical/public performance and synchronization.

Through staking BAND NFTs, the holder can earn crypto from both BAND NFT trades on the OpenSea NFT marketplace and from the BAND music catalog royalty revenue.

The company intends to sell three more series of BAND NFTs, with 3,000 NFTs in each series. This strategy would cap the supply of BAND NFTs at a maximum of 12,000 units. As these NFTs are staked to capitalize on royalty opportunities, the supply of BAND NFTs available for trade is expected to be reduced, which the company then expects would increase the value of the BAND NFTs moving forward.

Market Opportunity

The market for NFTs has exploded in 2021, driven by rising media coverage and mainstream awareness. A well-known example is the first tweet by Twitter CEO Jack Dorsey, which was sold as an NFT for the equivalent of $2.9 million in March. This growth has been particularly apparent for art-focused NFTs, spearheaded by digital artist Beeple, who sold an NFT series titled “Everyday: The First 5000 Days” for over $69 million at auction during that same month.

The performance of the NFT space hasn’t just been confined to those big-ticket items. OpenSea, the largest NFT marketplace, reported monthly sales of over $95 million in February 2021 alone, up from $8 million the previous month. In total, over $400 million in NFT trading had taken place on the ethereum blockchain as of early April, with nearly half taking place from February to March 2021.

As Reuters reports, enthusiasts view NFTs as the future of ownership, and they solve the problem of monetization for digital artwork. Importantly, the report notes that “NFTs could also transform music.” The industry seems to agree.

In March 2020, Kings of Leon released their latest album, When You See Yourself, in the form of an NFT – a milestone in the history of the entertainment industry.

BAND Royalty is uniquely positioned to capitalize on the shifting landscape surrounding digital ownership as it continues to roll out its series of BAND NFTs in the months to come.

BAND Royalty Founders

The name BAND is the combination of the founders’ initials, Barnaby Andersun and Noble Drakoln.

Barnaby Andersun (BA) has spent years developing blockchain and cryptocurrency solutions, acting as CEO of BlockAlchemy, a blockchain, ecommerce and digital design consulting firm. Being involved in all aspects of web technologies since their conception in the early nineties has made Mr. Andersun a true pioneer in web development, ecommerce, branding, online marketing and blockchain. A sought-after international speaker, Mr. Andersun has been invited to speak on cryptocurrencies at Harvard and World Economic Forum, Davos, where he coordinated a blockchain digital asset conference, as well as Stanford University.

Noble Drakoln (ND) has been an avid music royalty investor for decades. He is also CEO of WarePlay Games Inc., a mobile AR/XR game design and development studio. Having started out as a futures and commodities broker at the age of 19 trading the E-mini S&P, gold futures contracts and treasury bond strips, he went on to author the Wiley & Sons-published best-selling books ‘Winning the Trading Game’ and ‘Trade Like a Pro’. Along with being a tech investor, financial author and sought-after speaker, Mr. Drakoln has been a contributing writer to Forbes and Futures Magazine, and a radio and T.V. financial commentator on Bloomberg and Fox Business News.

BAND Royalty is operated by Singapore based LIBERTY IS PTE. LTD, located at 23 New Industrial Road #04-09 Solstice Business Center Singapore 536209.

Recent News

• BAND Royalty Pre-Sales $700,000 In BAND NFTs, Innovative Music Royalty NFTs
• As NFTs Drive Ethereum Market Growth, BAND Royalty Officially Launched Their Own NFT Marketplace beta on May 15th
• InvestorNewsBreaks – BAND Royalty Co-Founders Featured on Recent Dealmaker Show Interview

Healthy Extracts Inc. (HYEX)

The QualityStocks Daily Newsletter would like to spotlight Healthy Extracts Inc. (HYEX).

Healthy Extracts Inc. (OTCQB: HYEX) was featured today in a publication from BioMedWire, examining how new research done by a team from the University of Florida has uncovered evidence that links the manifestation of neurodegenerative diseases such as Parkinson’s, Alzheimer’s and ALS to the presence of specific bacteria types in the gut. Previous research had pointed to gut microbiota changes in people who suffered from neurodegenerative conditions. However, the huge diversity of bacteria in the digestive tract made it a daunting task to pinpoint the specific bacteria types connected to neurodegenerative diseases. This is the challenge that the University of Florida team took head on.

Healthy Extracts Inc. (HYEX) Healthy Extracts Inc. (HYEX), through its growing portfolio of wholly owned subsidiaries, is engaged in the proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. The company’s focus is to advance its market positions in the broader health industry through the unique assets and operations of its science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries and to offer better lifestyles through superior health technology.

BergaMet North America

BergaMet NA is engaged in the sale and distribution of a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit™ called “bergamot.” Bergamot is native to Southern Italy and is naturally sourced and uniquely loaded with various antioxidant polyphenols. Thanks to this composition, bergamot supports and promotes overall wellness specific to cholesterol, cardiovascular and metabolic health with no known side effects.

BergaMet NA is the only Citrus Bergamot SuperFruit™ heart health supplement backed by 17 clinical studies. The BergaMet brand supplement boasts the highest quality and concentration of polyphenols and flavonoids available anywhere in the world. It is also the only bergamot supplement approved by the prestigious Accademia del Bergamotto of Italy. BergaMet NA is the only company authorized to manufacture, distribute and sell these products in the United States, Canada and Mexico.

Consumers are including the Citrus Bergamot SuperFruit™ in their everyday personal health programs. The clinically proven antioxidant provides benefits to tens of thousands of people daily.

The company’s line of products can be found at www.bergametna.com, through Amazon, other online retailers and in doctors’ offices throughout the United States.

The BergaMet Advantage

BergaMet has been studied in 17 published clinical trials which reported results of lower LDL cholesterol, higher HDL cholesterol, lower triglycerides, lower blood pressure, lower blood glucose, increased arterial function, improved liver function and is effective as a complement to statin use.

Cardiovascular disease is the number one cause of death in the U.S. and worldwide, claiming nearly 18 million lives each year accounting for 31% of all global deaths. In the U.S., statins are one of the most commonly prescribed medicines for cardiovascular disease. The Centers for Disease Control estimates that 28% of American women and men over the age of 40 take a statin to lower the amount of cholesterol in the blood.

Taking aim at this market for cardiovascular care, BergaMet NA continues to advance the awareness of its medical-grade supplements and separate its formulation from competitors.

BergaMet NA products contain 47% BPF (bergamot polyphenolic fraction), while its closest competitors have only 38%. The company’s increased dosages (600-675mg vs 500mg) and 47% BPF are clinically proven to be more effective in improving heart health and metabolic syndrome.

BergaMet Citrus Bergamot SuperFruit™ supplements:

• Support healthy immune systems with powerful antioxidants and proprietary formulations.
• Reduce cholesterol and support healthy glucose and blood pressure levels.
• Are fully organic, vegan-friendly and dairy, gluten, soy and GMO-free.
• Contain five key unique flavonoids that make up the most powerful 47% BPF (bergamot polyphenolic fraction) in the world, providing superior results compared to their competitors.
• Have been clinically shown to increase arterial elasticity while reducing arterial and muscle inflammation.

Ultimate Brain Nutrients

Healthy Extracts’ Ultimate Brain Nutrients (“UBN”) subsidiary is a science-based company that develops unique, plant-based superior health technology neuro-products that improve brain health, including memory, cognition, focus and neuro-energy.

UBN’s KETONOMICS® proprietary formulations – targeting brain activity, focus, headache and cognitive behavior — provide multiple intellectual property license opportunities for monetizing the company’s portfolio.

License opportunities include multiple beverage formats, individual products, proprietary mixtures and other food platforms.

UBN has five unique formulation patents – one issued and four pending – targeting brain activity, focus, headache and cognitive behavior.

The UBN Advantage

UBN’s all-natural, sugar-free and caffeine-free proprietary formulations are the result of 20 years of scientific research and are positioned to provide consumer neuro-products that are natural brain solutions. UBN has filed for approval to the U.S. Food and Drug Administration (FDA) to make a Qualified Health Claim for its migraine formulation, tapping into consumer demands for healthy beverages that contribute to brain health, overall well-being and performance.

Over 50 million Americans consume unhealthy energy shots and drinks each day, while the neuro/energy market generates over $10 billion per year in revenue. Within this growing market, UBN is advancing its position to meet rising consumer demand for healthy, science-based options. The company’s KETONOMICS® proprietary formulations have been proven to naturally elevate brain energy and function, including memory, cognition and focus.

UBN’s KETONOMICS® supplementation has also been studied in sports physiology, with specific regard to its potential benefits for competitive performance and endurance.

Healthy Extracts Executive Team

Kevin “Duke” Pitts, Director, President and Chief Operating Officer

• Started and built from the ground up two multi-million-dollar businesses, one of which grew into a Top 100 retailers in the U.S.
• Unique management skills led to the development of successful teams for 35 years
• Pioneered direct marketing for a Fortune 200 company, creating a 20% increase in targeted incremental sales
• Founded Einstein’s Hemp, which developed and brought to market one of the only odorless and tasteless water-soluble CBD products in the world
• Developed and implemented digital/guerrilla marketing strategies for public and private companies focused on long-term brand position and acquisition efforts
• Specialized in customer relationship management (CRM) tools for creating the best customer experiences
• Worked in publicly traded industries for 10 years, overseeing up to $20 million in annual marketing budgets

William “Bill” Bossung, Director, Chief Financial Officer

• 35 years of diverse experience in corporate finance, insurance and accounting
• 20 years of experience with IPOs focusing on audits, FINRA and SEC regulations
• Specializes in the formation of capital raising over $100 million, recently raising $12 million for Splash Beverage
• Specializes in upgrading penny stocks companies to the NYSE or Nasdaq
• Involved in 30+ companies transitioning from private to public identities
• Founded several companies, including BCF Technology Inc., which sold to Vertafore; managing partner at Bishop Equity Partners LLC; director at Splash Beverage Group; and director of finance at Chadmoore Wireless, where he licensed channels to Nextel for $162 million

Bill Croyle, Director, Private Investor and Accomplished Senior Executive

• More than 40 years of success in the IT, energy, manufacturing, telecommunications, venture capital and finance industries
• Broad expertise includes negotiating mergers and acquisitions, as well as service and delivery contracts
• Formerly was a founder, owner or executive of EnTX Group; Impact Legacy Partners; FB Oilfield Special Tools; and Western Energy Advisors

Dr. Gerald Haase, Chief Medical Officer

• Clinical professor of surgery at the University of Colorado, School of Medicine
• Actively involved in medical research and clinical trials for 35 years
• Received U-10 grant funding from the National Institutes of Health cooperative group clinical trials program, as well as U.S. Congressional funding for Cooperative Research and Development Agreements with the Department of Defense and NASA
• Was chairman of the Department of Pediatric Surgery at Children’s Hospital Colorado; consultant surgeon to the Department of the Army; vice-chairman of the Children’s Cancer Group, a cooperative research consortium of the National Cancer Institute; on the National Board of Directors of the American Cancer Society; a senior member of the Commission on Cancer of the American College of Surgeons; and a member of the editorial board of The Annals of Surgical Oncology
• Has published 180 scientific papers and is the inventor or co-inventor of 12 issued U.S. patents for micronutrient and phytonutrient therapy, with five pending patents
• Recipient of clinical research grants and contracts funded at a several million-dollar cumulative level
• Is an editorial reviewer for medical journals and a member of numerous professional societies, including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences and American College of Physician Executives

Healthy Extracts Inc. (HYEX), closed Wednesday’s trading session at $0.0708, even for the day, on 16,905 volume. The average volume for the last 3 months is 31,607 and the stock's 52-week low/high is $0.052000001/$0.100000001.

Recent News

• New Study Links Neurodegenerative Diseases to Gut Bacteria Changes
• BioMedNewsBreaks - Healthy Extracts Inc. (HYEX) Poised for Opportunity in Burgeoning Global Health Products Sector
• Healthy Extracts Inc. (HYEX) Announces Association Of Dr. Kahn With The Healthy Extracts Inc. Medical Board

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

• Music streaming companies like Spotify Technology S.A. (NYSE: SPOT) and Apple Inc. (NASDAQ: AAPL) have come under fire recently for not sustaining artist livelihood because the revenue structure they offer does not truly benefit musicians. In the United States, the Union of Musicians and Allied Workers (“UMAW”) was formed to help ensure that musical artists are being paid their fair share of royalties from streaming services. The goal is to create a more just relationship with labels and create safer guidelines for venues. The primary target of the UMAW seems to be Spotify, with the Union demanding: Under Spotify’s current structure, artists are paid a portion of subscription fees based on the popularity of their music streams. The more popular you are, the higher the potential to earn revenue. Spotify isn’t alone. Many music streaming services utilize the same structure. But Fan Pass, a music streaming platform and application from Friendable (OTC: FDBL), takes the traditional revenue structure and puts its own spin on it. Through the Fan Pass structure, artists earn a portion of the monthly subscription revenue, much like Spotify, but artists who set up ticketed live-streamed events also earn the revenue from their ticket sales. These artists can leverage their fan base for income, not only from monthly subscription revenue, but ticket and merchandise sales as well.
• Friendable (OTC: FDBL), a mobile technology and marketing company, recently announced that it has entered beta phase version 2 of its Fan Pass mobile and desktop application. The release will feature an all-new design, technological advancements, quicker artist onboarding, backstage VIP access, better navigation, and scalable social media. Friendable anticipates release of version 2 of Fan Pass in early June 2021 and looks forward to implementation of the innovative enhancements designed to benefit both the fans and artists who use the platform. Friendable’s CEO Robert A. Rositano was quoted in a recent article, where he stated, “With entirely new and updated technologies, UI, UX designs, and general interactions and enhancements made on the platform, our team is extremely excited about rolling out version 2 of Fan Pass to our current artists, new artists and their fans.” To view the full article, visit https://ibn.fm/MZrQy

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

• Live performances or online concerts
• Backstage meetups before, during or after events
• Livestreams of studio sessions
• Behind-the-scenes footage of music video and photo shoots
• Special interviews and one-on-one videos
• Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Wednesday’s trading session at $0.0165, even for the day, on 274,406 volume. The average volume for the last 3 months is 4,424,219 and the stock's 52-week low/high is $0.007799999/$0.174999997.

Recent News

• Friendable Inc.'s (FDBL) Fan Pass Platform Offers Important Alternative Revenue Streams, While Traditional Music Streaming Companies Face Criticism
• InvestorNewsBreaks - Friendable Inc. (FDBL) Preparing for Release of v2 Fan Pass
• Friendable, Inc.'s (FDBL) Fan Pass Projecting Growth in All Business Areas, Laying Successful Foundation for V2 Release